Moreover, a decrease in phospho NFκB-p65 levels in leukocytes from T2D patients at 24 weeks of empagliflozin treatment (Figure 3E; p < 0.05) was observed. The gene discussed is NFKB1; the disease is type 2 diabetes mellitus.